Figure 1
Figure 1. Subject disposition. gE/AS01B, glycoprotein E/liposome-based adjuvant (50 µg MPL, 50 µg QS21); gE/AS01E, glycoprotein E/liposome-based adjuvant (25 µg MPL, 25 µg QS21); SAEs, serious adverse events. *Four subjects (2 in the gE/AS01E and 2 in the saline groups) with confirmed HZ were included in the safety analysis but were excluded from the immunogenicity analyses at month 15.

Subject disposition. gE/AS01B, glycoprotein E/liposome-based adjuvant (50 µg MPL, 50 µg QS21); gE/AS01E, glycoprotein E/liposome-based adjuvant (25 µg MPL, 25 µg QS21); SAEs, serious adverse events. *Four subjects (2 in the gE/AS01E and 2 in the saline groups) with confirmed HZ were included in the safety analysis but were excluded from the immunogenicity analyses at month 15.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal